Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success
Elena Inzoli, Andrea Aroldi, Rocco Piazza, Carlo Gambacorti‐Passerini
Abstract
TKI discontinuation proved to be safe and feasible in patients with CML with deep and durable molecular responses, introducing an additional treatment goal for these patients beyond overall survival. However, treatment interruption is a safe procedure only with appropriate patient selection and monitoring. Clinical and biological factors associated with better outcomes do not yet offer a precise stratification of patients according to their risk of relapse. This article aims at reviewing the leading studies present in the field in order to define eligibility criteria for discontinuation and predictors of success.
Topics & Concepts
DiscontinuationMedicineMyeloid leukemiaIntensive care medicineRisk stratificationOncologyInternal medicineTyrosine-kinase inhibitorCancerChronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia ResearchEosinophilic Disorders and Syndromes